Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$129.66−5.63 (-4.16%)
Close on Nov 13, 2026Market cap $5.42BP/E –Yield –
Veradermics r&d expenses
Research and development expenses are spending on new products and technology.
Veradermics's R&D Expenses for the twelve months ending Sep 30, 2026 was $73.80M. For fiscal 2025 it was $62.07M, up 166.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.07M | +166.6% |
| FY2024 | Dec 31, 2024 | $23.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.08M | -11.2% |
| Q2 FY2026 | Jun 30, 2026 | $18.61M | +29.9% |
| Q1 FY2026 | Mar 31, 2026 | $20.93M | +82.8% |
| Q4 FY2025 | Dec 31, 2025 | $18.19M | – |
| Q3 FY2025 | Sep 30, 2025 | $18.10M | – |
| Q2 FY2025 | Jun 30, 2025 | $14.33M | – |
| Q1 FY2025 | Mar 31, 2025 | $11.45M | – |
See a number that looks wrong?